Mesoblast (MESO) Projected to Post Quarterly Earnings on Thursday

Mesoblast (NASDAQ:MESO) will likely be releasing its Q2 2026 results after the market closes on Thursday, February 26th. Analysts expect Mesoblast to post earnings of ($0.2370) per share and revenue of $30.6790 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, January 28, 2026 at 6:00 PM ET.

Mesoblast Stock Performance

NASDAQ:MESO opened at $16.52 on Wednesday. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -18.77 and a beta of 2.15. The business has a 50 day moving average of $18.00 and a 200 day moving average of $16.87. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.99 and a quick ratio of 1.77. Mesoblast has a 1-year low of $9.61 and a 1-year high of $21.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new stake in Mesoblast during the 1st quarter valued at $3,209,000. Creative Planning purchased a new stake in shares of Mesoblast during the second quarter worth about $141,000. Raymond James Financial Inc. bought a new stake in shares of Mesoblast in the second quarter worth about $86,000. JPMorgan Chase & Co. increased its holdings in Mesoblast by 55.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after purchasing an additional 1,012 shares during the period. Finally, Legal & General Group Plc purchased a new position in Mesoblast during the 3rd quarter valued at about $10,501,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.